Giuseppe Cabibbo
@cabibbo78
Gastroenterologist & Hepatologist in Palermo with special interest in Hepatocellular Cancer.
ID:862347780404195328
10-05-2017 16:45:07
286 Tweets
352 Followers
218 Following
Follow People
Lorenza Rimassa
Associate Professor of Medical Oncology at HUNIMED, GI cancer specialist with research interest in #livercancer, #HCC, #biliarytractcancer, #cholangiocarcinoma
Maria Reig
Head of BCLC group. Liver Unit. Hospital Clinic Barcelona. IDIBAPS. Ciberehd.
David James Pinato 🇺🇦
Medical Oncologist, MD PhD, Director of Developmental Therapeutics @ImperialCollege & @UniAvogadro ❤️ HCC, Immunotherapy and drug development. 🇮🇹 🇬🇧 🏳️🌈
BCLC GROUP
The BCLC group was created in 1986. We are a multidisciplinary group dedicated to the management and research in liver cancer.
JC Garcia Pagan
Easter is over. Instead of an egg, we received the link to the review written with our Italian and German friends. Giuseppe Cabibbo Ciro Celsa Lorenza Rimassa Roman Kloeckner Was fun to debate around trial design for HCC.
journal-of-hepatology.eu/article/S0168-…
Hospital Clínic IDIBAPS CIBERehd
Dinner with friends. Behind the scenes at the “56th Annual Meeting of the Italian Association for the Study of the Liver”.
AISF - Associazione Italiana Studio Fegato Vincenza Calvaruso Giuseppe Marrone V. La Mura, R. D'Ambrosio Virginia Erica Villa Duilio Pagano Valerio Giannelli Marco Senzolo quirino lai
What a beautiful place, what a meaningful time AISF - Associazione Italiana Studio Fegato Vincenza Calvaruso Giuseppe Cabibbo Alessio Aghemo quirino lai Salvatore Piano Marco Carbone Alessio Gerussi Francesca Romana Ponziani Sherrie Bhoori Ana Lleo Francesco Paolo Russo and many others
laura.crocetti presenting ablation approach for #HCC proposed our multiparametric therapeutic multiparametric approach EASL Education #livercancersummit Giuseppe Cabibbo andrea casadei gardini Alessandro Vitale David James Pinato 🇺🇦 Umberto Cillo AISF - Associazione Italiana Studio Fegato
ascopubs.org/doi/10.1200/JC… This relates to renal cancer, but concepts about DFS apply to liver also. They raise Time To Treatment failure as end-point. This is proposed in our ABC-HCC trial testing TACE vs systemic clinicaltrials.gov/study/NCT04803… EASLnews AASLD ILCA ESMO - Eur. Oncology ...
